Transcode Therapeutics, Inc. (RNAZ) stock
Close on Nov 16, 2026Market cap $1.37MP/E –Yield –
Earnings
Transcode Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Transcode Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q1 FY2024ended Mar 31, 2024 | Apr 5, 2024after the close | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Jan 16, 2024after the close | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 14, 2023after the close | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 31, 2023after the close | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022after the close | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 15, 2022after the close | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 16, 2022after the close | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 15, 2021after the close | – | – | -$0.20 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 23, 2021after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Transcode Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Transcode Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Transcode Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- Update
- News
- Update
- Update
- Update
- Update
- Update
- News
- News
- News
- Update
- Update
- News
See a number that looks wrong?